.
Although recurrent peritonitis, with the accompanying decreased permeability of the perito- Hitherto, no evidence has been found that CAPD more efficiently removes those solutes that cause neurological symptoms. To measure the differences in solute concentrations in sera of patients treated with CAPD or with HD, we have used a screening method based on "high-performance" liquid chromatography (HPLC), as described previously (10) .
Materials and Methods

Patients and Sera
Blood was sampled from 15 patients on H]) treatment and 12 patients on CAPD. For hemodialysis we used Disscap 160 dialyzers (Cuprophan, Hospal, Meyzieu, France), a blood flow of 300 mL/min, and a dialysate flow of 500 mL/min. CAPD was performed with four 2-L exchanges within 24 h. HD samples were taken before dialysis. CAPD patients were sampled in the outpatient department, more or less randomly during their daily routine bag exchange. Table 1 summarizes patient characteristics.
None of the CAPD patients had symptoms of peritonitis. The two patients changing the mode of therapy volunteered to do so; they had no clinical indication, such as peritonitis or problems with vascular access. Although the group of CAPD patients had been receiving (any) dialysis treatment for a shortertime, we found no significant difference in residual creatinine clearance between this group and the HI) group. All patients were treated at least for three months with the method specified.
Procedures
Protein binding. Protein binding was measured by ultrafiltration through "Centrifree" ultrafiltration units (Amicon Corp., Danvers, MA). We subjected 1-mL aliquots of serum to ultrafiltration by centrifi.igation in the units,at 22 #{176}C, at an angle of 30#{176}, and at 1900 x g, then determined the "free" (i.e., not protein bound) fractions of the solutes in the ifitrate. To measure the total concentrations (i.e., bound and nonbound),we precipitated proteins by adding 50 pL of a 100 g/L solution of trichloroacetic acid (TCA) to 1 mL of serum, after treatment by ultrasonication. Then we centrifuged and ultrafiltered the samples, as described for the determination of free fractions. All Centrifree filtrates were analyzed by HPLC, after addition of an internal standard, naphthalenesulfonic acid. We checkedfor any decomposition of uremic solutes caused by the added TCA and found the following losses, which we took into account in the calculations: pseudouridine3.6%, tyrosine 3.9%, indoxyl sulfate 6.7%, an unknown fluorescent peak TJKF7A (see Figure 1 below) 10%, and indole-3-acetic acid 10%. Concentrations of all solutes in subsequent ultrafiltrates (collected at 20-mm intervals) were constant, indicating that protein binding was maintained at equilibrium during ultraiiltration. This was not completely true for tryptophan and indoxyl sulfate, however, the concentrations of which increased slightly during ultrafiltration. For these solutes, we used the values obtained by extrapolation to zero ultrafiltration time. Protein binding (PBL, %) was calculated as follows:
Variable
where Cf is the concentration of free solute, and C is the total concentration.
HPLC. HPLC analysis was performed as described previously (10). We used a 4. Gas chromatography/mass spectrometry. For gas chromatography/mass spectrometry analysis we used a Model HP 5970A mass-selective detector coupled to an HP 5790A gas chromatograph (both from Hewlett Packard, Avondale, PA), equipped with a 40-m CPSII5 capillary column (Chrompack, Middelburg, The Netherlands).
The fraction corresponding to HPLC peak 2 ( Figure 1 ) was isolated by repeated HPLC separation and collection, was lyophilized, then derivatized with bis(trimethylsilyl)trifluoroacetamide (Pierce Chemical Co., Rockford, IL), and injected into the gas chromatograph through a fallingneedle solidsinjector. 
Results
The present study was divided into two parts. First, we analyzed and compared the concentrationsof accumulated solutesin bloodof two groupsof patients, on CAPD (n = 12) and HI) (n = 15). Second, we alsodetermined the concentrations longitudinally in two patients changing therapy: one from CAPD to HD and the otherviceversa. Characteristic HPLC profiles of the solutes are presented in Figure 1 , both as absorbance and fluorescence traces. The unknown peak previously designated as UK6 (10) was identified by us by mass spectrometry as p-hydroxyhippuric acid.
Mass-spectrometric investigation also showed that the peak previously identified tentatively as uracil (10) where. The differences between the HPLC profflesshown in Figure 1 will be discussed below.
Comparing the CAPD and the HO Patients
The free (non-protein-bound)
fractions and the total concentrations of the solutes under study are summarized in Tables 2 and 3. The data for the H]) group were measured before dialysis. Obviously, comparing these bloodconcentrations is not very informative because the HI) group is sampled in a worst-case condition with respect to the high predialysis blood concentrations. Therefore, for statistical analysis, all concentrations in the individual samples were standardized with respect to the corresponding creatinine concentrations:
where C1 is concentration of component i, CREA is the corresponding creatinine concentration (in pmol/L), and is the "standardized" concentration. Creatinine was taken as the reference because it is more "constant" than urea, and because it is widely used as a marker in clinical practice. For the sake of unambiguity, we report the original (nonstandardized) concentrations in Tables 2 and 3 . However, we applied Wilcoxon's test to both the nonstandardized and the standardized data. The standardized blood concentration of PSI is significantly higher (P <0.0001) in the CAPD group than in the HI) group, as is also true for UKF5 (P <0.025) ( Table 2 ). The standardized concentrations of PSI, calculated from the original data by using equation 1, are 76.3 and 38.7 mmol/ mol creatinine for CAPD and HI) patients, respectively. Although average concentrations of a number of solutes such as hippunic acid and p-hydroxyhippunic acid appear to differ, this difference was not significant for these numbers of patients and the observed among-patient variance.
For none of the solutes was protein binding significantly different between the HD and CAPD groups (Table 4) , by bivariate statistical analysis.
To study the differences in the profiles by considering the relation of the solutes one to the other, we used a multivariate approach, stepwise discriminant analysis (11). By stepwise selection both for free and total concentrations of the solutes at a significance level ofF = 0.05, only the variables PSI and unknown fluorescent compound UKF3 were selected. This means that the combination of these two variables contributed most to distinguishing the HI) and CAPD groups; moreover, the influence of the combination was more than that of PSI alone, as was found by bivaniate analysis of the standardized concentrations. Further analysis of the data showed that the serum concentrations of PSI and UKF3 were significantly during experiments on selective isolation of PSI. Nucleosides (e.g., PSI) are known to be extracted selectively by solid-phase extraction on boronate gel (12) . Performing this procedure, we extracted not only PSI, but also UKF3, with approximately equal recovery.This supports the suggestion that UKF3 is a fluorescent nucleoside, a carbohydrate, a glucuronide, or somesolutewith a cis-diol group. Moreover, the solute is present abundantly in normal urine, but has not hitherto been identified decisively.
Effects of Changing Therapy
We monitored the concentrations of the uremic solutes in blood of two patients who were changing therapy. One patient (K) volunteered to go from HD to CAPD therapy, and the other (R) changed therapy from CAPD to HI) for reasons of lifestyle. Blood was sampled from both patients one month before the changeover, during the equilibration period,and then for another several weeks. Representative In accordance with the data on the patients shown above, the most striking and significant change was the high no PSI/CREA ratio in the CAPD intervals of both patients. In addition, the UKF3IPSI ratio changed even more signifia cantly, as illustrated in Figure 4 CAPD period. These results are summarized in Table 5 .
-p--m/z Fig. 2 . Electron impact mass spectrum of thmethy1sillated, isolated Discussion HPLC peak 2 (see Fig.1 ),which is identical to that of a similarly The most striking difference between UD and CAPD sera derivatized pseudouridinestandard demonstrated in the HPLC proffles centers around pseu- Two possible explanations of the high concentrations of PSI in serum from CAPD patients will be discussed here. (29) . The PSI/CREA ratio in anabolic as well as catabolic processes was evaluated, and children with "failure to thrive" showed a marked depression of tRNA catabolites (30). Perhaps the higher serum PSIJCREA ratio in CAPD patients than in HD patients indicates a better noncatabolic status in CAPD. CAPD treatmentreportedly is more beneficial to growth of children than is H]) (31, 32), probably as a result of better homeostasis and more free diet, despite the risk of undernutrition from treatment-induced anorexia.
It has been reported that urinary PSI excretion is positively related to protein intake (33). However, the PSI] CREA ratio in normal individuals is closer to that in HI) patients than to that in CAPD patients. Normal concentrations of PSI in serum have been reported as 2.48 (SD 0.13) izmollL (measured by HPLC) (34) and 1.72 (SD 0.77) jmoIJL (measured by RIA) (35) . For a normal serum creatimne value of 80 mol/L, a normal serum PSJJCREA ratio would be 20-30 mniollmol, similar to the normal value for this ratio in urine. However, because healthy individuals ordinarily have neutral or positive nitrogen balance and nonrestricted protein intake, the foregoing seems to invalidate the suggestion that the high PSIJCREA ratio in CAPD is related to protein intake or protein synthesis, or both. Nonetheless, secondary effects associated with the derangement state of uremia are not unthinkable. No hard data were available on differences in diet between the groups of patients. To assess the metabolic state and (or) the influence of diet, careful clinical control of the different variables in a further study is indicated.
Less significant was our observation of the somewhat decreased concentrations of hippuric acid and p-hydroxyhippm-ic acid in CAPD patients than in HI) patients. In a precedingpilot studyinvolvingsevenpatients on CAPD and three on HI), a similar observation was made. In the present study, hippuric acid decreased very significantly with the onset of CAPD for a patient changing therapy. In conclusion: we found that pseudouridine concentrations in serum of CAPD patients are significantly higher than in HD patients. This difference is even more significant when concentrations are standardized to serum creatinine concentration.
Further study is needed to answer the question whether low peritoneal membrane permeability, specific tRNA turnover, asymptomatic peritonitis accompanied by cell death, or another as-yet-unrecognized cellular process is the origin of the high pseudouridine concentrations in CAPD.
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